Search
Powered By HealthLine
Health Tools
 Allergy Questions and Answers
 Allergic Reaction Guide
 Seasonal Allergies Guide
 Is it a Cold or Allergies?
 Food Allergy Guide
Featured Conditions
 Allergy
 Asthma
 Diet & Exercise
 Sleep
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & PrecautionsAdditional Info
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Ortho Tri-Cyclen

[Noregestimate/Ethinyl Estradiol]


Clinical Pharmacology
CLINICAL PHARMACOLOGY

ORAL CONTRACEPTION

Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).

Text Continues Below



Receptor binding studies, as well as studies in animals and humans, have shown that norgestimate and 17- deacetyl norgestimate, the major serum metabolite, combine high progestational activity with minimal intrinsic androgenicity. Norgestimate, in combination with ethinyl estradiol, does not counteract the estrogen-induced increases in sex hormone binding globulin (SHBG), resulting in lower serum testosterone.

ACNE Acne is a skin condition with a multifactorial etiology. The combination of ethinyl estradiol and norgestimate may increase sex hormone binding globulin (SHBG) and decrease free testosterone resulting in a decrease in the severity of facial acne in otherwise healthy women with this skin condition.

Norgestimate and ethinyl estradiol are well absorbed following oral administration of ORTHO-CYCLEN and ORTHO TRI-CYCLEN. On the average, peak serum concentrations of norgestimate and ethinyl estradiol are observed within two hours (0.5-2.0 hr for norgestimate and 0.75-3.0 hr for ethinyl estradiol) after adminis-tration followed by a rapid decline due to distribution and elimination.

Although norgestimate serum concentrations following single or multiple dosing were generally below assay detection within 5 hours, a major norgestimate serum metabolite, 17-deacetyl norgestimate, (which exhibits a serum half-life ranging from 12 to 30 hours) appears rapidly in serum with concentrations greatly exceeding that of norgestimate. The 17-deacetylated metabolite is pharmacologically active and the pharmacologic profile is similar to that of norgestimate. The elimination half-life of ethinyl estradiol ranged from approximately 6 to 14 hours.

Page:  1 | 2 | Next >>







HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire